Lumretuzumab

Lumretuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetERBB3
Clinical data
Other namesRG7116
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6512H10064N1736O2052S44
Molar mass146916.88 g·mol−1

Lumretuzumab (INN; development code RG7116) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by Genentech/Roche.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.